LA
LAB.US Standard Biotools Inc
- Market cap
- USD 279M
- P/E
- -
- P/B
- 0.50x
- ROE
- -14.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LAB.US undervalued?
Graham numberThe Graham number of Standard Biotools Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Standard Biotools Inc fundamental analysis
No fundamental analysis for Standard Biotools Inc yet.
Standard Biotools Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides So…
Full company profileStandard Biotools Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Standard Biotools Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 104M | 102M | 113M | 117M | 138M | 131M | 97.9M | 106M | 174M | 85.3M | 80.8M |
| Gross Profit | 58.4M | 52.0M | 61.6M | 64.3M | 83.3M | 77.3M | 37.1M | 50.5M | 84.3M | 42.5M | 43.6M |
| Operating Income | -73.2M | -58.4M | -48.2M | -51.8M | -51.0M | -67.5M | -116M | -76.6M | -175M | -93.3M | -72.8M |
| EBITDA | -56.4M | -39.4M | -31.0M | -46.6M | -34.6M | -44.3M | -174M | -54.5M | -118M | -85.7M | -73.4M |
| Net Income | -76.0M | -60.5M | -59.0M | -64.8M | -53.0M | -59.2M | -190M | -74.7M | -139M | -74.9M | -78.0M |
| EPS | -2.62 | -1.84 | -1.49 | -0.97 | -0.74 | -0.78 | -2.43 | -0.94 | -0.39 | -0.20 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 306M | 287M | 304M | 265M | 325M | 275M | 390M | 323M | 612M | 568M | 635M |
| Total Liabilities | 253M | 256M | 232M | 111M | 186M | 181M | 472M | 471M | 141M | 143M | 79.6M |
| Shareholders' Equity | 53.2M | 30.9M | 72.1M | 154M | 139M | 94.6M | -81.5M | -148M | 472M | 424M | 556M |
| Cash & Short-term Investments | 59.4M | 63.1M | 95.4M | 58.6M | 68.5M | 28.5M | 166M | 115M | 293M | 188M | 461M |
| Total Debt | 195M | 195M | 172M | 60.0M | 95.4M | 112M | 103M | 98.2M | 33.0M | 30.8M | 26.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -39.1M | -24.1M | -25.2M | -35.2M | -15.4M | -44.1M | -89.4M | -43.3M | -143M | -74.4M | -84.1M |
| Capital Expenditure | 5.07M | 1.62M | 372K | 2.53M | 12.7M | 13.3M | 3.83M | 2.83M | 8.36M | 8.30M | 1.22M |
| Free Cash Flow | -44.2M | -25.7M | -25.6M | -37.7M | -28.1M | -57.3M | -93.2M | -46.1M | -152M | -82.7M | -85.3M |
| Ratios | |||||||||||
| ROE | -142.7% | -195.7% | -81.8% | -42.2% | -38.1% | -62.6% | - | - | -29.4% | -17.7% | -14.0% |
| ROA | -24.8% | -21.1% | -19.4% | -24.5% | -16.3% | -21.5% | -48.7% | -23.1% | -22.7% | -13.2% | -12.3% |
| Net Profit Margin | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -79.6% | -87.8% | -96.5% |
| Debt to Equity | 3.66x | 6.31x | 2.39x | 0.39x | 0.69x | 1.18x | - | - | 0.07x | 0.07x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Standard Biotools Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 299K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | USD 1.50M | 0.02 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Standard Biotools Inc
- Insiders 1.85%
- Institutions 74.57%
- Public & others 23.58%
- Shares outstanding 395M
- Free float 188M
Top funds holding LAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 8.68M | 2.20% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 2.92M | 0.74% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.48M | 0.37% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.37M | 0.35% | -0.38% | Sep 2026 |
| Neuberger Intrinsic Value I | 1.04M | 0.26% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 684K | 0.17% | +0.11% | Sep 2026 |
| Morgan Stanley Inst Inception I | 655K | 0.17% | 0.00% | Jun 2026 |
| Fidelity Total Market Index | 558K | 0.14% | -0.05% | Sep 2026 |
| iShares Healthcare Innov ETF USD Acc | 521K | 0.13% | 0.00% | Oct 2026 |
| EQ/Morgan Stanley Small Cap Growth K | 504K | 0.13% | 0.00% | Sep 2026 |
| Neuberger US Sm Cp Intrs Val USD I Acc | 480K | 0.12% | 0.00% | Jul 2026 |
| Fidelity Series Total Market Index | 474K | 0.12% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 338K | 0.09% | +0.03% | Oct 2026 |
| Global X Genomics & Biotech ETF USD Acc | 325K | 0.08% | +0.42% | Oct 2026 |
| Column Small Cap Select | 305K | 0.08% | 0.00% | Sep 2026 |
| Global X Genomics & Biotechnology ETF | 248K | 0.06% | +2.52% | Oct 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 194K | 0.05% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 179K | 0.05% | +1.92% | Oct 2026 |
| Fidelity ZERO Total Market Index | 164K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 158K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding LAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Casdin Capital, LLC | 88.8M | 22.49% | 0.00% | Jun 2026 |
| Viking Global Investors LP | 58.7M | 14.86% | 0.00% | Jun 2026 |
| Mak Capital One LLC | 28.8M | 7.30% | +10.09% | Jun 2026 |
| Long Focus Capital Management, LLC | 23.5M | 5.95% | +46.73% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.3M | 3.10% | -4.39% | Jun 2026 |
| BlackRock Inc | 8.25M | 2.09% | -66.66% | Jun 2026 |
| Hollow Brook Wealth Management, LLC | 5.20M | 1.32% | -5.50% | Sep 2026 |
| Neuberger Berman Group LLC | 4.96M | 1.26% | +6.46% | Jun 2026 |
| Qube Research & Technologies | 4.82M | 1.22% | +584.33% | Jun 2026 |
| Royce & Associates, LP | 4.53M | 1.15% | +50.57% | Jun 2026 |
| Geode Capital Management, LLC | 3.90M | 0.99% | -46.54% | Jun 2026 |
| Tikvah Management LLC | 3.55M | 0.90% | 0.00% | Jun 2026 |
| Millennium Management LLC | 3.51M | 0.89% | +67.11% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.83M | 0.72% | -1.92% | Jun 2026 |
| D. E. Shaw & Co LP | 2.82M | 0.71% | +1,315.50% | Jun 2026 |
| Jane Street Group LLC | 2.51M | 0.64% | 0.00% | Jun 2026 |
| Peapod Lane Capital LLC | 2.41M | 0.61% | +18.88% | Jun 2026 |
| Citadel Advisors Llc | 2.35M | 0.60% | +91.67% | Jun 2026 |
| Mink Brook Asset Management LLC | 2.19M | 0.56% | 0.00% | Jun 2026 |
| Sone Capital Management | 2.13M | 0.54% | +20.76% | Jun 2026 |
Standard Biotools Inc company profile
- Company name
- Standard Biotools Inc
- Ticker
- LAB.US
- Exchange
- USA Stocks
- Listed since
- Jul 29, 2003
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 385
- Fiscal year end
- December
- Address
- 50 Milk Street, Boston, MA, United States, 02109
- Phone
- 650 266 6000
- Website
- standardbio.com
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Standard Biotools Inc management
8- Dr. Michael Egholm Ph.D.President, CEO & Director · born 1963
- Mr. Hanjoon KimChief Financial Officer · born 1971
- Mr. Sean MackaySenior VP & Chief Business Officer · born 1982
- Mr. Jonathan MickelsenVP & Chief Accounting Officer
- John GrazianoVice President of Investor Relations
- Ms. Elizabeth R. JensenChief Human Resources Officer · born 1974
- Mr. Anders DavasSenior Vice President of Global Operations
- Mr. Mike MusgnugSenior VP & Chief Commercial Officer